Your Current Position: NEWS
-
Oct. 19, 2018. Professor Michel L. Tremblay from McGill University visited Converd and had a proactive communication with our scientists.
-
【Industry Trends】 Sep. 13, 2018 Boehringer Ingelheim buyed an oncolytic virus R&D company called ViraTherapeutics in $244M deal2018-09-14On Sep. 13, 2018, the German company Boehringer Ingelheim (BI) announced the acquisition of Vira Therapeutics, an oncolytic virus research and development company based in Austria.
-
【Company News】 Wu Weizhong, Director of the Institute of Liver Cancer, Zhongshan Hospital, visited Converd2018-07-05Wu Weizhong, the Director of the Institute of Liver Cancer and Deputy Director of Cell Therapy Research Center of Zhongshan Hospital affiliated to Fudan University
-
【Company News】 Nanjing Legend Biotechnology Company's Chief Strategy Officer Dr. Zhu Li visited Converd2018-07-05Dr Zhu Li, the Chief Strategy Officer of Nanjing Legend Biotechnology Co., visited Converd and had in-depth communication with Dr. Hu Fang, Chairman of Converd,
-
【Industry Trends】 J Clin Invest 128(4): The mechanism of tumor resistance to oncolytic viruses discovered2018-06-07An article entitled "PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy" published online in the J Clin Invest indicates that PD-L1
-
2018-05-15In Nature, a news titled “Cancer killing viruses show promise – and draw billion-dollar investment” mentioned, pharmaceutical giant Johnson & Johnson announced on 2
-
【Company News】 Converd’s clinical trial of using oncolytic virus in combination with immunotherapy for gastrointestinal cancers2018-04-30Converd has initiated a phase I/II clinical trial: A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer agent (A01) with Immune Cells (IC01) in patients with Advanced Gastrointestinal Cancer.
-
【Company News】 A clinical study of CAR-NK for treatment of metastatic solid tumors is conducted by Converd’s subsidiary, Hangzhou Youshan Sictech Ltd.2018-04-30This clinical study has started in the in the 3rd hospital of Guangzhou Medical University. It is designed to evaluate safety and efficacy of a novel CAR-NK cell therapy for patients with an advanced cancer.
-
On Feb. 22, 2018, Merck and Viralytics announced acquisition agreement and the proposed acquisition values the total issued shares in Viralytics at approximately AUD 502 million (USD 394 million).
-
【Company News】 Deputy Dean Xv Xuehu and Director Sheng Xiujie of the Third Affiliated Hospital of Guangzhou Medical University came to Converd for academic exchange2018-02-22On January 13, 2018, Deputy Dean Xv Xuehu and Director Sheng Xiujie of the Third Affiliated Hospital of Guangzhou Medical University came to our company for academic exchanges.